These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20651367)

  • 21. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
    Velikyan I; Xu H; Nair M; Hall H
    Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide.
    Melo IB; Ueda LT; Araujo EB; Muramoto E; Barboz MF; Mengatti J; Buchpiguel CA; Silva CP
    Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):31-6. PubMed ID: 20525456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.
    Melis M; Valkema R; Krenning EP; de Jong M
    J Nucl Med; 2012 May; 53(5):749-53. PubMed ID: 22496587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
    Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
    J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiolabeling of PAMAM dendrimers conjugated to a pyridine-N-oxide DOTA analog with ¹¹¹In: Optimization of reaction conditions and biodistribution.
    Biricová V; Lázničková A; Lázníček M; Polášek M; Hermann P
    J Pharm Biomed Anal; 2011 Nov; 56(3):505-12. PubMed ID: 21757312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
    Petrik M; Laznickova A; Laznicek M; Zalutsky MR
    Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
    Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.
    Froidevaux S; Eberle AN; Christe M; Sumanovski L; Heppeler A; Schmitt JS; Eisenwiener K; Beglinger C; Mäcke HR
    Int J Cancer; 2002 Apr; 98(6):930-7. PubMed ID: 11948475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
    Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.
    Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M
    Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticancer activity of targeted proapoptotic peptides.
    Capello A; Krenning EP; Bernard BF; Breeman WA; Erion JL; de Jong M
    J Nucl Med; 2006 Jan; 47(1):122-9. PubMed ID: 16391196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.
    Liu Z; Pourghiasian M; Bénard F; Pan J; Lin KS; Perrin DM
    J Nucl Med; 2014 Sep; 55(9):1499-505. PubMed ID: 24970911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
    van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
    J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lanreotide labeled with 99mTc: preparation, preclinical testing and comparison with (111)In-DTPA-octreotide.
    Laznicek M; Laznickova A; Trejtnar F; Lorenc P; Varvarigou A; Bouziotis P; Archimandritis S
    Anticancer Res; 2002; 22(4):2125-30. PubMed ID: 12174893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
    Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
    Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy.
    de Jong M; Breeman WA; Bernard BF; Rolleman EJ; Hofland LJ; Visser TJ; Setyono-Han B; Bakker WH; van der Pluijm ME; Krenning EP
    Eur J Nucl Med; 1995 Jul; 22(7):608-16. PubMed ID: 7498221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution, elimination, and renal handling of (99m)technetium-Demogastrin 1.
    Trejtnar F; Laznickova A; Laznicek M; Novy Z; Maina T; Nock BA; Behe M
    Cancer Biother Radiopharm; 2012 Mar; 27(2):169-74. PubMed ID: 22409267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.